persevERA is the first of two distinct phase III studies in the first-line setting; pionERA study of giredestrant in combination with physician’s choice of CDK4/6 inhibitor in endocrine-resistant ...
persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus ...
Phase 3 persevERA missed the primary endpoint, with no statistically significant improvement in investigator-assessed PFS for giredestrant plus palbociclib versus letrozole plus palbociclib in the ITT ...
Oppenheimer analyst Matthew Biegler notes that Olema (OLMA) shares are up today, likely on news that Roche’s (RHHBY) evERA trial was a success. “No, that’s not the trial we’ve all been waiting for,” ...
Roche announced results from the phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human ...
persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...
persevERA Breast Cancer [NCT04546009] is a Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of giredestrant plus palbociclib versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results